Webinar Series - 3- & 5-year INTERCEPT Experiences

Program Description

This webinar provides a report of the experience of two blood centers that have integrated INTERCEPT pathogen inactivation technology for platelets into routine practice, including impact on blood center operations and inventory management.

Dr. Jean-Pierre Cazenave presents his 3-year experience for the EFS Alsace, a regional center that provides blood components for 2 million inhabitants of the Alsace region. Dr. Jean-Claude Osselaer reports on his 5-year experience for the Blood Transfusion Center of Mont-Godinne, a hospital-based transfusion service that supports a 400 bed specialized care medical center.

The presentation includes a rigorous statistical analysis of blood product usage and safety patterns, evaluating whether the universal adoption of pathogen inactivated INTERCEPT platelet concentrates affected component utilization by patients or production requirements. This data directly addresses the functional equivalence of INTERCEPT treated blood components to untreated components.

Topics to be discussed

• Operational experience with INTERCEPT platelets
• Impact on product inventory, shelf-life, wastage rates, and donor utilization
• INTERCEPT reception by transfusing physicians
• 36- and 60-month data regarding the impact on platelet utilization and adverse events
• Longitudinal safety data for repeated exposure and for patients supported with both platelets and plasma
• Support of pediatric patients, patients with congenital bleeding disorders, and bone marrow transplant patients
• Replacement or avoidance of gamma irradiation, CMV serology and bacterial detection
• Subset analysis of intensively transfused Hematology and Oncology patients
• Platelet consumption per day of support
• RBC usage
• Per patient utilization of blood components

 Speaker Bios

Dr. Jean-Pierre Cazenave EFS-Alsace, Strasbourg, France Dr. Cazenave has been Director of the Blood Transfusion Center in Strasbourg since 1987. Dr. Cazenave is Professor of Hematology and Transfusion at University Louis Pasteur, Faculty of Medicine of Strasbourg, member of several international societies and author of 500 publications. He has more recently devoted his research to experimental models of platelet transfusion and to clinical studies of pathogen inactivation of blood components.

Dr. Jean-Claude Osselaer Transfusion Center, Cliniques Universitaires de Mont-Godinne, Universite Catholique de Louvain, Yvoir, Belgium Dr. Osselaer has been the Head of the Apheresis Unit, Blood Bank and Tissue- Typing Laboratory at the Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium since 1992. In 1999, he also became Medical Director of the newly created Blood Transfusion Centre (BTC) of Mont-Godinne, and combines this role with Medical Directorship of the BTC of Charleroi. He is a member of several international associations in the field of transfusion and apheresis.

Return to webinar schedule